@misc{10481/94888,
year = {2023},
month = {5},
url = {https://hdl.handle.net/10481/94888},
abstract = {Despite exhaustive studies, researchers have made little progress in the field of adoptive
cellular therapies for relapsed/refractory acute myeloid leukemia (AML), unlike the notable uptake
for B cell malignancies. Various single antigen-targeting chimeric antigen receptor (CAR) T cell Phase
I trials have been established worldwide and have recruited approximately 100 patients. The high
heterogeneity at the genetic and molecular levels within and between AML patients resembles a
black hole: a great gravitational field that sucks in everything. One must consider the fact that only
around 30% of patients show a response; there are, however, consequential off-tumor effects. It is
obvious that a new point of view is needed to achieve more promising results. This review first
introduces the unique therapeutic challenges of not only CAR T cells but also other adoptive cellular
therapies in AML. Next, recent single-cell sequencing data for AML to assess somatically acquired
alterations at the DNA, epigenetic, RNA, and protein levels are discussed to give a perspective on
cellular heterogeneity, intercellular hierarchies, and the cellular ecosystem. Finally, promising novel
strategies are summarized, including more sophisticated next-generation CAR T, TCR-T, and CAR
NK therapies; the approaches with which to tailor the microenvironment and target neoantigens; and
allogeneic approaches.},
organization = {Biomedicine Program of the University of Granada
(Spain)},
organization = {PECART-0027-2020 funded by Consejería de Salud y Familias},
organization = {ProyExcel_00875
Consejería de Transformación Económica, Industria, Conocimiento y Universidades},
organization = {COST Action (CA21113), supported by COST (European Cooperation in Science
and Technology)},
publisher = {MDPI},
keywords = {Acute myeloid leukemia},
keywords = {Cellular therapies},
keywords = {Chimeric antigen T cells},
title = {The Black Hole: CAR T Cell Therapy in AML},
doi = {10.3390/cancers15102713},
author = {Atilla, Erden and Benabdellah, Karim},
}